Form 6K argenx NV ADR For: 20 March
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
argenx NV ADR (ARGX)
argenx NV ADR stock price, this page displays NASDAQ ARGX stock exchange data. View the ARGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the argenx NV ADR real time stock price chart below.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
679.27
+15.34(+2.31%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
678.70
692.84
52 wk Range
510.06
934.62
ARGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
678.70692.84
52 wk Range
510.06934.62
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARGX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
1,014.13
Upside
+49.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
- Form 6K argenx NV ADR For: 20 March
- Investing.com
- Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
argenx NV ADR SWOT Analysis
Vyvgart's Triumph | Explore argenx's meteoric rise in biotech, driven by Vyvgart's success in treating autoimmune diseases and its recent approval for CIDP treatment |
Financial Milestones | Delve into argenx's robust financial health, with a market cap of $39.27B, 85.56% revenue growth, and projected profitability by fiscal year 2025 |
Market Dominance | Learn how argenx is solidifying its position in gMG and CIDP markets, with over 50% of new Vyvgart patients switching from oral treatments |
Future Horizons | Analysts project long-term revenue potential of $8B by 2033, with price targets ranging from $468 to $725, reflecting confidence in argenx's growth |
argenx NV ADR Earnings Call Summary for Q4/2025
- Argenx Q4 2025 EPS of $8.02 beat forecast of $5.95 by 34.79%; revenue reached $1.29B, slightly above $1.28B estimate.
- Full-year 2025 product sales surged 90% YoY; company achieved first annual operating profit of $1.1B with Q4 net profit of $533M.
- U.S. market drove growth with 68% YoY sales increase, representing 84.6% of Q4 revenue; VYVGART remains core growth driver.
- Stock fell 3.1% to $791.64 in pre-market despite earnings beat; analysts maintain bullish outlook with price targets of $641-$1,318.
- 2026 guidance projects revenue of $5.93B with EPS forecast of $7.57-$9.88; CEO cites label expansions and pipeline advancement as growth catalysts.
Last Updated: 26-02-2026, 08:40 pm
Read Full TranscriptCompare ARGX to Peers and Sector
Metrics to compare | ARGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.9x | 27.1x | −0.5x | |
PEG Ratio | 0.61 | 0.46 | 0.00 | |
Price/Book | 5.8x | 3.8x | 2.6x | |
Price / LTM Sales | 10.0x | 3.0x | 3.1x | |
Upside (Analyst Target) | 52.8% | 46.4% | 57.5% | |
Fair Value Upside | Unlock | 25.2% | 8.1% | Unlock |
Analyst Ratings
20 Buy
3 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 1,014.13
(+49.30% Upside)
Earnings
Latest Release
26-02-2026
EPS / Forecast
8.02 / 5.95
Revenue / Forecast
1.29B / 1.28B
FAQ
What Is the argenx ADR (ARGX) Stock Price Today?
The argenx ADR stock price today is 679.27.
What Stock Exchange Does argenx ADR Trade On?
argenx ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for argenx ADR?
The stock symbol for argenx ADR is "ARGX."
What Is the argenx ADR Market Cap?
As of today, argenx ADR market cap is 42.31B.
What Is argenx ADR's Earnings Per Share (TTM)?
The argenx ADR EPS (TTM) is 19.57.
When Is the Next argenx ADR Earnings Date?
argenx ADR will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is ARGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has argenx ADR Stock Split?
argenx ADR has split 0 times.
How Many Employees Does argenx ADR Have?
argenx ADR has 1863 employees.
What is the current trading status of argenx ADR (ARGX)?
As of 23-03-2026, argenx ADR (ARGX) is trading at a price of 679.27, with a previous close of 663.93. The stock has fluctuated within a day range of 678.70 to 692.84, while its 52-week range spans from 510.06 to 934.62.
What Is argenx ADR (ARGX) Price Target According to Analysts?
The average 12-month price target for argenx ADR is USD1,014.13, with a high estimate of USD1219.10401292 and a low estimate of USD691.12084871. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +49.30% Upside potential.
What Is the ARGX Premarket Price?
ARGX's last pre-market stock price is 683.84. The pre-market share volume is 5,820.00, and the stock has decreased by 19.91, or 3.00%.
What Is the ARGX After Hours Price?
ARGX's last after hours stock price is 677.09, the stock has decreased by 13.16, or 1.98%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.